Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter phase 2 study of Bruton’s tyrosine kinase inhibitor PCI-32765 in relapsed or refractory mantle cell lymphoma
2010-022939-11Phase 2Completed
- Sponsor
- Pharmacyclics
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib in mantle cell lymphoma (MCL), sponsored by Pharmacyclics. Primary endpoint: Overall response rate. Started Feb 2011; status: completed.
02
Drugs
ibrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2010-022939-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022939-11.